ATE402717T1 - Für die termini des beta-amyloids spezifische, rekombinante antikörper, dafür kodierende dna und verfahren zu ihrer verwendung - Google Patents
Für die termini des beta-amyloids spezifische, rekombinante antikörper, dafür kodierende dna und verfahren zu ihrer verwendungInfo
- Publication number
- ATE402717T1 ATE402717T1 AT98918035T AT98918035T ATE402717T1 AT E402717 T1 ATE402717 T1 AT E402717T1 AT 98918035 T AT98918035 T AT 98918035T AT 98918035 T AT98918035 T AT 98918035T AT E402717 T1 ATE402717 T1 AT E402717T1
- Authority
- AT
- Austria
- Prior art keywords
- amyloid
- beta
- terms
- antibodies specific
- recombinant antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4185097P | 1997-04-09 | 1997-04-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE402717T1 true ATE402717T1 (de) | 2008-08-15 |
Family
ID=21918670
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT98918035T ATE402717T1 (de) | 1997-04-09 | 1998-04-09 | Für die termini des beta-amyloids spezifische, rekombinante antikörper, dafür kodierende dna und verfahren zu ihrer verwendung |
Country Status (16)
Country | Link |
---|---|
US (2) | US20090069258A1 (de) |
EP (3) | EP0994728B1 (de) |
JP (3) | JP3816111B2 (de) |
CN (1) | CN1177616C (de) |
AT (1) | ATE402717T1 (de) |
AU (1) | AU743827B2 (de) |
CA (1) | CA2286305A1 (de) |
CY (1) | CY1110371T1 (de) |
DE (1) | DE69839808D1 (de) |
DK (1) | DK0994728T3 (de) |
ES (1) | ES2312185T3 (de) |
IL (1) | IL132262A (de) |
NZ (1) | NZ337765A (de) |
PT (1) | PT994728E (de) |
SI (1) | SI0994728T1 (de) |
WO (1) | WO1998044955A1 (de) |
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8173127B2 (en) * | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US6743427B1 (en) | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
AU2008203784B2 (en) * | 1999-05-28 | 2012-01-19 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidogenic disease |
UA81216C2 (en) * | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
AUPQ180499A0 (en) | 1999-07-23 | 1999-08-19 | Biomolecular Research Institute Limited | Beta-amyloid peptide inhibitors |
EP1307219A4 (de) * | 1999-08-13 | 2005-04-06 | Univ Columbia | Verfahren zur hemmung der bindung von beta-faltblattfibrillen an rage( advanced glycation endproduct receptor ) |
ES2275570T3 (es) * | 1999-12-08 | 2007-06-16 | Intellect Neurosciences, Inc. | Peptidos amiloides beta quimericos. |
NZ520800A (en) | 2000-02-24 | 2004-04-30 | Univ Washington | Humanised monoclonal antibodies that sequester amyloid beta peptide so as to prevent its deposition in the brain |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
US6815175B2 (en) | 2001-03-16 | 2004-11-09 | Cornell Research Foundation, Inc. | Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder |
DE60230736D1 (de) | 2001-04-30 | 2009-02-26 | Lilly Co Eli | HUMANISIERTE ANTIKÖRPER DIE DAS BETA-AMYLOID PEPTID ERKENNEN& x9; |
EP1385544B1 (de) | 2001-04-30 | 2008-09-24 | Eli Lilly And Company | Humanisierte antikörper |
DK1944040T3 (da) | 2001-08-17 | 2012-10-29 | Univ Washington | Analysefremgangsmåde for Alzheimers sygdom |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
JP2006513259A (ja) * | 2002-07-24 | 2006-04-20 | イノジェネティックス・ナムローゼ・フェンノートシャップ | ベータ−アミロイド生成および/または凝集に関連した疾病の防止、処置および診断 |
WO2004029629A1 (en) * | 2002-09-27 | 2004-04-08 | Janssen Pharmaceutica N.V. | N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses |
MXPA05003621A (es) * | 2002-10-09 | 2005-10-19 | Rinat Neuroscience Corp | Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos. |
ATE468886T1 (de) | 2003-02-10 | 2010-06-15 | Applied Molecular Evolution | Abeta-bindende moleküle |
US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
TWI306458B (en) | 2003-05-30 | 2009-02-21 | Elan Pharma Int Ltd | Humanized antibodies that recognize beta amyloid peptide |
BRPI0516572A (pt) * | 2004-10-05 | 2008-09-16 | Wyeth Corp | métodos e composições para melhorar a produção de proteìnas recombinantes |
GB0424563D0 (en) | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
AR052051A1 (es) | 2004-12-15 | 2007-02-28 | Neuralab Ltd | Anticuerpos ab humanizados usados en mejorar la cognicion |
US7906625B2 (en) | 2005-01-24 | 2011-03-15 | Amgen Inc. | Humanized anti-amyloid antibody |
JP5289963B2 (ja) * | 2005-10-21 | 2013-09-11 | メルク・シャープ・アンド・ドーム・コーポレーション | 抗addlモノクローナル抗体およびその使用 |
CN1329413C (zh) * | 2006-01-23 | 2007-08-01 | 南京医科大学 | 一种治疗或预防老年性痴呆的抗体及其表达载体和在制药中的应用 |
EP2177536B1 (de) * | 2006-03-30 | 2014-06-04 | Glaxo Group Limited | Antikörper gegen Amyloid-beta Peptid |
WO2009017467A1 (en) | 2007-07-27 | 2009-02-05 | Elan Pharma International Limited | Treatment of amyloidogenic diseases |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
KR20120017469A (ko) | 2007-01-05 | 2012-02-28 | 유니버시티 오브 취리히 | 질환 특이적 결합 분자 및 표적을 제공하는 방법 |
IL199534A (en) | 2007-01-05 | 2013-01-31 | Univ Zuerich | An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses. |
PL2104682T3 (pl) | 2007-01-11 | 2017-03-31 | Michael Bacher | Diagnostyka i leczenie choroby Alzheimera i innych chorób neurodegeneracyjnych |
EP1944315A1 (de) * | 2007-01-11 | 2008-07-16 | Philipps-Universität Marburg | Prophylaxe und Therapie von Morbus Alzheimer und anderen Demenzerkrankungen |
WO2008088983A1 (en) | 2007-01-18 | 2008-07-24 | Eli Lilly And Company | PEGYLATED Aβ FAB |
WO2008104580A1 (en) | 2007-03-01 | 2008-09-04 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
DK2142514T3 (da) | 2007-04-18 | 2015-03-23 | Probiodrug Ag | Thioureaderivater som glutaminylcyclase-inhibitorer |
EP2152309B1 (de) | 2007-05-14 | 2013-07-10 | Medtronic, Inc. | Verfahren und vorrichtung zur neutralisierung von löslichen giftstoffen im gehirn |
US8323654B2 (en) | 2007-05-14 | 2012-12-04 | Medtronic, Inc. | Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
HUE025150T2 (en) | 2008-12-19 | 2016-01-28 | Biogen Int Neuroscience Gmbh | Human anti-alpha-synuclein autoantibodies |
EP2258398A1 (de) | 2009-05-26 | 2010-12-08 | Araclón Biotech, S. L. | Albumin/Amyloidpeptid-Konjugate und deren Verwendungen |
CA2772488C (en) | 2009-09-11 | 2018-04-17 | Probiodrug Ag | Heterocyclic derivatives as inhibitors of glutaminyl cyclase |
EP2542549B1 (de) | 2010-03-03 | 2016-05-11 | Probiodrug AG | Glutaminylcyclase-hemmer |
EA022420B1 (ru) | 2010-03-10 | 2015-12-30 | Пробиодруг Аг | Гетероциклические ингибиторы глутаминилциклазы (qc, ec 2.3.2.5) |
WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
EP2598236A2 (de) * | 2010-07-30 | 2013-06-05 | Technische Universität Dortmund | Polymere komplemente von b-amylod-peptiden |
WO2012057363A1 (ja) * | 2010-10-27 | 2012-05-03 | 学校法人自治医科大学 | 神経系細胞への遺伝子導入のためのアデノ随伴ウイルスビリオン |
EP2686313B1 (de) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazolderivate als glutaminylcyclase-hemmer |
EP2691393B1 (de) | 2011-03-31 | 2016-09-14 | Pfizer Inc | Neue bicyclische pyridinone |
WO2012172449A1 (en) | 2011-06-13 | 2012-12-20 | Pfizer Inc. | Lactams as beta secretase inhibitors |
CN103796679B (zh) | 2011-06-23 | 2016-10-19 | 比奥根国际神经科学公司 | 抗-α突触核蛋白结合分子 |
EP2751116B1 (de) | 2011-08-31 | 2016-10-12 | Pfizer Inc | Hexahydropyrano [3,4-d][1,3] thiazin-2-aminverbindungen |
ES2585262T3 (es) | 2012-05-04 | 2016-10-04 | Pfizer Inc | Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2 |
PE20150153A1 (es) | 2012-06-29 | 2015-02-05 | Pfizer | 7H-PIRROLO[2,3-d]PIRIMIDINAS 4-(AMINO-SUBSTITUIDAS) NOVEDOSAS COMO INHIBIDORES DE LRRK2 |
EP2897964A1 (de) | 2012-09-20 | 2015-07-29 | Pfizer Inc. | Alkylsubstituierte hexahydro[3,4-d][1,3]thiazin-2-amin-verbindungen |
UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
JP2016502978A (ja) | 2012-12-11 | 2016-02-01 | ファイザー・インク | BACE1の阻害剤としてのヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物 |
JP6162820B2 (ja) | 2012-12-19 | 2017-07-12 | ファイザー・インク | 炭素環式および複素環式置換ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物 |
CA2897678A1 (en) | 2013-02-13 | 2014-08-21 | Pfizer Inc. | Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
US9233981B1 (en) | 2013-02-15 | 2016-01-12 | Pfizer Inc. | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
MD20150071A2 (ro) | 2013-02-19 | 2016-02-29 | Pfizer Inc. | Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni |
EP3052495B1 (de) | 2013-10-04 | 2019-06-26 | Pfizer Inc | Neuartige bicyclische pyridinone als gamma-sekretase-modulatoren |
CA2933767C (en) | 2013-12-17 | 2018-11-06 | Pfizer Inc. | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
CR20160454A (es) | 2014-04-01 | 2016-12-06 | Pfizer | CROMENO Y 1,1 a,2,7b—TETRAHIDROCICLOPROPA[C]CROMENO PIRIDOPIRAZINADIONAS NOVEDOSAS |
PE20170327A1 (es) | 2014-04-10 | 2017-04-21 | Pfizer | 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4d] [1,3] TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS |
JP6713982B2 (ja) | 2014-07-24 | 2020-06-24 | ファイザー・インク | ピラゾロピリミジン化合物 |
ES2733502T3 (es) | 2014-08-06 | 2019-11-29 | Pfizer | Compuestos de imidazopiridazina |
US10160799B2 (en) | 2014-11-19 | 2018-12-25 | Axon Neuroscience Se | Humanized tau antibodies in a alzheimer's disease |
MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
SG11201705780PA (en) | 2015-02-03 | 2017-08-30 | Pfizer | Novel cyclopropabenzofuranyl pyridopyrazinediones |
JP6827959B2 (ja) | 2015-06-17 | 2021-02-10 | ファイザー・インク | 三環式化合物およびホスホジエステラーゼ阻害剤としてのそれらの使用 |
RU2722149C1 (ru) | 2015-09-14 | 2020-05-27 | Пфайзер Инк. | Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2 |
JP2018531924A (ja) | 2015-09-24 | 2018-11-01 | ファイザー・インク | テトラヒドロピラノ[3,4−d][1,3]オキサジン誘導体、およびbace阻害剤としてのその使用 |
WO2017051294A1 (en) | 2015-09-24 | 2017-03-30 | Pfizer Inc. | N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors |
JP2018531923A (ja) | 2015-09-24 | 2018-11-01 | ファイザー・インク | N−[2−(2−アミノ−6,6−二置換−4,4a,5,6−テトラヒドロピラノ[3,4−d][1,3]チアジン−8a(8H)−イル)−1,3−チアゾール−4−イル]アミド |
RU2719599C2 (ru) | 2016-02-23 | 2020-04-21 | Пфайзер Инк. | Соединения 6, 7-дигидро-5H-пиразоло[5,1-b][1,3]оксазин-2-карбоксамида |
EP3872078A1 (de) | 2016-07-01 | 2021-09-01 | Pfizer Inc. | 5,7-dihydro-pyrrolo-pyridin-derivate zur verwendung für die behandlung von depression, angst oder panikstörungen |
CN111201226B (zh) | 2017-03-10 | 2022-07-22 | 辉瑞大药厂 | 环状被取代的咪唑并[4,5-c]喹啉衍生物 |
JP7219223B2 (ja) | 2017-03-10 | 2023-02-07 | ファイザー・インク | LRRK2阻害剤としての新規のイミダゾ[4,5-c]キノリン誘導体 |
JP2020523035A (ja) | 2017-06-07 | 2020-08-06 | エーディーアールエックス, インコーポレイテッド | タウ凝集阻害剤 |
PL3642202T3 (pl) | 2017-06-22 | 2023-03-13 | Pfizer Inc. | Pochodne dihydropirolopirydyny |
CA3073062A1 (en) | 2017-08-18 | 2019-02-21 | Adrx, Inc. | Tau aggregation peptide inhibitors |
RS64289B1 (sr) | 2017-08-22 | 2023-07-31 | Biogen Ma Inc | Farmaceutske kompozicije koje sadrže anti-amiloid beta antitela |
PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
CN112154145B (zh) | 2018-03-23 | 2023-10-17 | 辉瑞大药厂 | 哌嗪氮杂螺衍生物 |
CN112074605B (zh) * | 2018-05-08 | 2024-11-22 | 纽洛可科学有限公司 | 抗fam19a5抗体的腺相关病毒(aav)递送 |
AU2019304384A1 (en) | 2018-07-17 | 2021-01-28 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-abeta antibody, antigen-binding fragment thereof and application thereof |
WO2022182658A1 (en) | 2021-02-23 | 2022-09-01 | Hoth Therapeutics, Inc. | Use of aprepitant for treating alzheimer's disease |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4185097A (en) | 1978-01-09 | 1980-01-22 | A. H. Robins Company, Inc. | Method of combating Herpes simplex viruses with lignosulfonates |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4870009A (en) | 1982-11-22 | 1989-09-26 | The Salk Institute For Biological Studies | Method of obtaining gene product through the generation of transgenic animals |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
GB8719963D0 (en) | 1987-08-24 | 1987-09-30 | Cattaneo A | Recombinant dna products |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
EP0683234B2 (de) * | 1993-01-25 | 2007-06-06 | Takeda Chemical Industries, Ltd. | Antikörper gegen beta-amyloid oder derivative davon und seine verwendung |
US5877399A (en) | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
US5688651A (en) * | 1994-12-16 | 1997-11-18 | Ramot University Authority For Applied Research And Development Ltd. | Prevention of protein aggregation |
US5786180A (en) * | 1995-02-14 | 1998-07-28 | Bayer Corporation | Monoclonal antibody 369.2B specific for β A4 peptide |
US5965614A (en) * | 1996-11-22 | 1999-10-12 | Athena Neurosciences, Inc. | N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US8173127B2 (en) * | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
-
1998
- 1998-04-09 EP EP98918035A patent/EP0994728B1/de not_active Revoked
- 1998-04-09 DK DK98918035T patent/DK0994728T3/da active
- 1998-04-09 AU AU71034/98A patent/AU743827B2/en not_active Ceased
- 1998-04-09 NZ NZ337765A patent/NZ337765A/en not_active IP Right Cessation
- 1998-04-09 EP EP08011798A patent/EP2006303A1/de not_active Withdrawn
- 1998-04-09 SI SI9830913T patent/SI0994728T1/sl unknown
- 1998-04-09 WO PCT/US1998/006900 patent/WO1998044955A1/en active IP Right Grant
- 1998-04-09 PT PT98918035T patent/PT994728E/pt unknown
- 1998-04-09 CA CA002286305A patent/CA2286305A1/en not_active Abandoned
- 1998-04-09 EP EP10011650A patent/EP2305709A1/de not_active Withdrawn
- 1998-04-09 AT AT98918035T patent/ATE402717T1/de active
- 1998-04-09 JP JP54304398A patent/JP3816111B2/ja not_active Expired - Fee Related
- 1998-04-09 CN CNB988035464A patent/CN1177616C/zh not_active Expired - Fee Related
- 1998-04-09 ES ES98918035T patent/ES2312185T3/es not_active Expired - Lifetime
- 1998-04-09 DE DE69839808T patent/DE69839808D1/de not_active Expired - Lifetime
-
1999
- 1999-10-07 IL IL132262A patent/IL132262A/en not_active IP Right Cessation
-
2005
- 2005-07-20 JP JP2005210196A patent/JP2005320349A/ja active Pending
-
2007
- 2007-05-08 US US11/745,759 patent/US20090069258A1/en not_active Abandoned
-
2008
- 2008-10-30 CY CY20081101230T patent/CY1110371T1/el unknown
-
2009
- 2009-05-07 JP JP2009113001A patent/JP2009173680A/ja active Pending
-
2010
- 2010-01-21 US US12/691,046 patent/US20110027279A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO1998044955A1 (en) | 1998-10-15 |
SI0994728T1 (sl) | 2009-02-28 |
DE69839808D1 (de) | 2008-09-11 |
EP0994728B1 (de) | 2008-07-30 |
US20110027279A1 (en) | 2011-02-03 |
CN1254294A (zh) | 2000-05-24 |
JP2002503092A (ja) | 2002-01-29 |
JP2009173680A (ja) | 2009-08-06 |
IL132262A (en) | 2009-11-18 |
ES2312185T3 (es) | 2009-02-16 |
AU7103498A (en) | 1998-10-30 |
EP2006303A1 (de) | 2008-12-24 |
EP0994728A4 (de) | 2001-11-28 |
JP2005320349A (ja) | 2005-11-17 |
CA2286305A1 (en) | 1998-10-15 |
DK0994728T3 (da) | 2008-12-01 |
EP2305709A1 (de) | 2011-04-06 |
AU743827B2 (en) | 2002-02-07 |
US20090069258A1 (en) | 2009-03-12 |
PT994728E (pt) | 2008-11-11 |
CN1177616C (zh) | 2004-12-01 |
NZ337765A (en) | 2001-09-28 |
JP3816111B2 (ja) | 2006-08-30 |
EP0994728A1 (de) | 2000-04-26 |
CY1110371T1 (el) | 2015-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE402717T1 (de) | Für die termini des beta-amyloids spezifische, rekombinante antikörper, dafür kodierende dna und verfahren zu ihrer verwendung | |
EP0971033A3 (de) | Prüfung und Modell für Alzheimers-Krankheit | |
NZ296748A (en) | Peripheral nervous system specific sodium channel proteins, DNA coding therefor, compositions and methods | |
ATE329028T1 (de) | Nl3 tie rezeptortyrosinekinase ligandhomologe | |
BR9710968A (pt) | Antìgenos de célula b humana; reagentes correlatos | |
ATE135371T1 (de) | Mit akuter pankreatitis assoziiertes protein, mittel zur diagnose von akuter pankreatitis | |
ATE368688T1 (de) | Peptide, deren herstellung und verwendung zur bindung von immunglobulinen | |
IL85878A0 (en) | Anticoagulant proteins,dna coding for them,processes for preparing them,pharmaceutical compositions containing them,monoclonal antibodies against such proteins and hybrid cell lines which secrete these antibodies | |
BR9912455A (pt) | ácidos nucléicos codificadores de proteìnas envolvidas em transdução sensória | |
DE69532033D1 (de) | Für ein fibroblasten-aktivierungsprotein kodierende nukleinsäure und verwendungen dafür | |
EP0873132A4 (de) | Bindendes Protein für Genprodukt der Huntingtonschen Krankheit, kodierende cDNA und Antikörper | |
EP0643719A4 (de) | Für den interleukin-9-rezeptor kodierende nukleinsäuresequenzen bzw. dafür komplementäre nuleinsäuresequenzen. | |
AUPP627498A0 (en) | Novel peptides - i | |
NZ294019A (en) | Proteins associated with the hippocampus; dna sequences coding therefor, antibodies to the proteins | |
DK1129191T3 (da) | Fremgangsmåder til diagnosticering eller behandling af neurologiske sygdomme | |
ATE321789T1 (de) | Antikörper und antisensmoleküle für g-gekoppeltes rezeptor mit selektiver affinität für atp | |
TW342413B (en) | Novel toxins isolated from Bracon Hebetor | |
ATE351909T1 (de) | Neue peptidfragmente zur reinigung von proteinen | |
IL142664A0 (en) | Prv-1 gene, processes for detecting the prv-1 polypeptide and pharmaceutical compositions containing the same | |
WO2002074793A3 (en) | Novel peptides for the diagnosis of schizophrenia | |
ATE198218T1 (de) | Htfiiia gen | |
DE59611353D1 (de) | Transketolase-verwandtes protein | |
EP1700866A3 (de) | Transporter organischer Anionen des Gehirns und dessen Gen | |
ITRM950434A0 (it) | Polipeptide per la riparazione di informazione genetica, sequenza nucleotidica che codifica per esso e procedimento per la sua preparazione. | |
ATE329046T1 (de) | Parvovirus-vektoren und deren verwendung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0994728 Country of ref document: EP |